Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 268.21B P/E 20.64 EPS this Y 440.40% Ern Qtrly Grth 68.80%
Income 2.31B Forward P/E 13.76 EPS next Y 23.70% 50D Avg Chg -4.00%
Sales 61.4B PEG 0.17 EPS past 5Y -11.65% 200D Avg Chg -3.00%
Dividend 3.00% Price/Book 5.73 EPS next 5Y 93.11% 52W High Chg -12.00%
Recommedations 1.80 Quick Ratio 0.73 Shares Outstanding 2.53B 52W Low Chg 25.00%
Insider Own 0.05% ROA 10.26% Shares Float 2.53B Beta 0.39
Inst Own 78.75% ROE 5.31% Shares Shorted/Prior 24.57M/19.47M Price 105.70
Gross Margin 74.85% Profit Margin 3.76% Avg. Volume 7,449,562 Target Price 143.28
Oper. Margin 42.47% Earnings Date Jul 30 Volume 10,865,850 Change 0.40%
About Merck & Company, Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Company, Inc. News
05:50 AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
07/24/24 MSD reports positive topline data from Phase IIb/III RSV trial in infants
07/23/24 Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
07/23/24 Merck Announces Fourth-Quarter 2024 Dividend
07/23/24 Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?
07/23/24 Billionaires Are Loading Up on This Surging Dow Stock. Should You?
07/23/24 Merck & Co., Inc. (NYSE:MRK) is largely controlled by institutional shareholders who own 78% of the company
07/23/24 Merck claims late-stage study success for RSV antibody
07/23/24 Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
07/23/24 Nanotechnology in medicine: Who are the leading public companies?
07/18/24 Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
07/18/24 Insiders At Merck Sold US$12m In Stock, Alluding To Potential Weakness
07/18/24 3 High Yield Healthcare Giants With Consistent Dividend Growth: Johnson & Johnson, Merck, And Quest Diagnostics
07/16/24 Here for Good: Merck's Steadfast Commitment to Health Equity
07/16/24 3 Biotech Stocks to Buy in Case of Another Pandemic
07/16/24 Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
07/15/24 The Zacks Analyst Blog Highlights Exxon Mobil, Merck & Co, Qualcomm and Armanino Foods of Distinction
07/12/24 Goldman's year of the stock picker, bank earnings reaction : Market Domination
07/12/24 Top Research Reports for Exxon Mobil, Merck & Qualcomm
07/12/24 MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset
MRK Chatroom

User Image BloodyPortfolio Posted - 20 minutes ago

$VKTX Most contenders have fairly good efficacy but tolerability is what governs final commercial success. Drive for Show, Putt for Dough! For those interested parties, what more data you want? BL already gave you everything. The only missing piece is oral 100mg. If no BO by Sept. or Oct. we will likely need to wait for another 2 years. Hurry if you want to sit at the table with FDA for EOP2/P3. BL has 300yd drive and single putt out. It's time for you to concede! $MRK $PFE $REGN

User Image Pitbowl Posted - 1 hour ago

$MRK $MRMD $NVS $PFE $SYK Cannabis Icecream... MRMD https://www.youtube.com/shorts/KsYYrvMNybc

User Image Pitbowl Posted - 3 hours ago

$CVX $MDT $MRK $TMO $MRMD Nature's Heritage - Cannabis Marimed MRMD

User Image SniperPro Posted - 7 hours ago

$LXRX $BMY $NVS My bet is between BMY and NVS for INPEFA acquisition, both need a new drug to replace/improve their hf pipeline... We'll see if I get it right... DD pays off, if you go deep down the rabbit hole.... To be continue... $PFE $MRK ???

User Image RRCORNER Posted - 9 hours ago

$NWBO Ticking bomb here. Watch this interview (about 25-minute mark) where Les Goldman says he thinks the UK approval should be around late fall this year. If that is the case, then expect share price to begin moving up anytime between now and Octoberish. An approval would signal a gigantic move up in price with numbers that are too ridiculous to even speculate now. Looks like an excellent risk to reward ratio than could be a real life-changing investment. I have been down on the poor recent performance, but this video is very reassuring that we are now within inches to the goal line. I beleive they have combination trials with $MRK $BMY https://youtu.be/tosXVC7BfX4?si=LmjAnpWNuPCg2IyL

User Image biostock Posted - 12 hours ago

$MRK $SPY $XBI $QQQ $GOSS

User Image Ineedamilibucks Posted - 12 hours ago

$MRK can we just run back to 127 haha

User Image Ineedamilibucks Posted - 12 hours ago

$MRK 129 EOD

User Image BloodyPortfolio Posted - 12 hours ago

$VKTX very undervalued! Can $MRK $PFE still say " not interested in GLP1/GIP peptide injectables"? 3RD in commercial obesity market with efficacy/tolerability. No more chatters about manufacturing bottle neck. BL's beating the rush-hour traffic. 100mg oral to beat CT996 6.1% single handedly. We will beat MariTide in reaching the market with monthly shot!

User Image gabbs Posted - 12 hours ago

$VKTX a bidding war for this gem between $PFE and $MRK would be the icing on the cake here

User Image trplbiem Posted - 13 hours ago

$KTRA it's prob not even a sell at 4$. TuHura is the most hyped bio tech of year. This is a $MRK keytruda collaboration that over 25b in market cap. They will never settle the FTD here prior the merger. $VKTX

User Image Ineedamilibucks Posted - 14 hours ago

$MRK looking to Get into calls at open 🥱

User Image DonCorleone77 Posted - 17 hours ago

$MRK Merck receives positive CHMP opinion for KEYTRUDA plus Padcev Merck announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of KEYTRUDA, Merck's anti-PD-1 therapy, in combination with Padcev, an antibody-drug conjugate, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.

User Image BloodyPortfolio Posted - 1 day ago

$VKTX for the first time ever in my 30yrs in the market, I began to believe a partnership or BO with CVR will work out better for the current shareholders than flat out cash BO. BL delivered P3 Monthly 100mg DACRA weekly 2809 0214. 2735/2809 combo and small molecule should be the next big thing. C'mon $MRK, let's do 6 simultaneous P3s - obesity, T2DM, CVOT, CNS/CVA, superiority to Semaglutide and OSA. $MRK should not miss this window of opportunity during next 4-6 months. $vktx is significantly under-valued for its potential. Where is all the FUDsters with CDMO and scalability BS?

User Image SparkyReturns Posted - 1 day ago

$LLY Folks, XERIS already has collabs with big pharma REGN and AMGN. Will your company be next to use their delivery tech? AMGN even ditched HALO to go with XERS delivery system instead because higher concentrations and no need for refrigeration. Time is running out to get in below 2.50. Why am I so optimistic? 1. Stable and growing revenue base. Gvoke and Recorlev will report highest sales ever at next ER on Aug 8. 2. SubQ Levo (thyroid treatment) will solve administration issues for people with gastro issues/pills, $2-3B TAM. XERS has hinted about bringing on a partner to monetize value. 3. Will hear soon on collabs with Amgen, Regeneron, and Beta Bionics and will learn soon what the terms are of their upfront payments and milestone payments. 4. Tutes have been quietly loading up under 2.50, highest institutional ownership ever. Cheers! $NVO $JNJ $MRK

User Image Ineedamilibucks Posted - 1 day ago

$MRK the only safest play in the market today IMO

User Image mikeywo Posted - 1 day ago

$CKPT class 2 review so Samsung will be re-inspected. Submission classified as a complete response says that all issues in the first CRL have been addressed but follow up inspections could find new issues. Don’t put anything past the big pharma monopolies and paying off the FDA and paying off inspectors to find issues to keep a competitor with a superior product from reaching the market. The first crl has cost $CKPT and shareholders 10’s of millions of dollars and a second one would bankrupt this company at then hands of crooked big pharma companies like $MRK.

User Image FE123 Posted - 1 day ago

$PFE $GILD $LLY $MRK Topline Alzheimers Data to Be presented on Wed 31st $VCNX 600k float

User Image lion3539 Posted - 2 days ago

$MRK can we fkn breakout

User Image Trick17 Posted - 2 days ago

@SolarWind99 nobody at the moment. If I had to bet maybe $MRK , $JNJ and on the distant horizon $PFE and $GSK

User Image drjtiger Posted - 2 days ago

$MRK 👏

User Image seforim Posted - 2 days ago

$KPTI $INCY $GSK $MRK $AZN https://x.com/kinatsofrim/status/1816218892911665457

User Image Ineedamilibucks Posted - 2 days ago

$MRK gonna go up tomorrow.

User Image cherronn Posted - 2 days ago

$MRK easy 127 tmr

User Image Ineedamilibucks Posted - 2 days ago

$MRK not liking the sell off

User Image Ineedamilibucks Posted - 2 days ago

$MRK buy buy buy, 128 tomorrow

User Image Ineedamilibucks Posted - 2 days ago

$MRK 130? Friday?

User Image Ineedamilibucks Posted - 2 days ago

$MRK were the buyers at? 131 before earnings?

User Image Ineedamilibucks Posted - 2 days ago

$MRK bulls are in control I guess

User Image TaylorTwits Posted - 2 days ago

$MRK covids back!

Analyst Ratings
Morgan Stanley Equal-Weight Jul 11, 24
Cantor Fitzgerald Overweight Jun 20, 24
Cantor Fitzgerald Overweight Jun 18, 24
Cantor Fitzgerald Overweight Jun 4, 24
Truist Securities Buy Apr 26, 24
Cantor Fitzgerald Overweight Apr 18, 24
Berenberg Buy Apr 8, 24
Cantor Fitzgerald Overweight Apr 5, 24
Cantor Fitzgerald Overweight Apr 1, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Oosthuizen Johannes Jacobus President, U.S. Mark.. President, U.S. Market Nov 09 Sell 102.3841 2,081 213,061 18,191 11/13/23
DeLuca Richard R. EVP&Pres, Merck Anim.. EVP&Pres, Merck Animal Heallth Nov 08 Sell 105.0286 43,823 4,602,668 111,764 11/09/23
Oosthuizen Johannes Jacobus President, U.S. Mark.. President, U.S. Market Oct 30 Option 102.82 915 94,080 20,723 10/31/23
Davis Robert M Chairman, CEO & Pres.. Chairman, CEO & President Apr 28 Sell 114.93 143,329 16,472,802 271,817 04/28/23
Davis Robert M Chairman, CEO & Pres.. Chairman, CEO & President Apr 28 Option 56.04 143,329 8,032,157 415,146 04/28/23
Chattopadhyay Sanat Exe V-P & Pres. MMD Exe V-P & Pres. MMD Apr 13 Sell 115.07 134,055 15,425,709 04/14/23
Chattopadhyay Sanat Exe V-P & Pres. MMD Exe V-P & Pres. MMD Apr 13 Option 59.06 134,055 7,917,288 134,055 04/14/23
Romanelli Joseph President, Human Hea.. President, Human Health Int?l Feb 15 Sell 108.2201 5,000 541,100 20,284 02/16/23
MIZELL STEVEN EVP, Chief HR Office.. EVP, Chief HR Officer Feb 13 Sell 109.1003 1,815 198,017 33,085 02/14/23
MIZELL STEVEN EVP, Chief HR Office.. EVP, Chief HR Officer Feb 09 Sell 107.0013 5,000 535,006 34,900 02/10/23
MIZELL STEVEN EVP, Chief HR Office.. EVP, Chief HR Officer Feb 06 Sell 104.2546 4,436 462,473 39,900 02/08/23
Oosthuizen Johannes Jacobus President, U.S. Mark.. President, U.S. Market Nov 09 Sell 103.21 1,795 185,262 16,731 11/10/22
Davis Robert M CEO & President CEO & President Nov 09 Option 0 167,613 415,206 11/10/22
Davis Robert M CEO & President CEO & President Nov 09 Sell 102.84 167,613 17,237,321 247,593 11/10/22
FRAZIER KENNETH C Executive Chair Executive Chair Nov 07 Option 0 235,769 936,422 11/08/22
FRAZIER KENNETH C Executive Chair Executive Chair Nov 07 Sell 99.31 235,769 23,414,219 700,653 11/08/22
Oosthuizen Johannes Jacobus SVP, U.S. Market SVP, U.S. Market May 03 Option 87.1 907 79,000 14,961 05/05/22
Garay Arpa SVP Human Health Glo.. SVP Human Health Global Mktg. May 03 Option 87.1 907 79,000 2,368 05/05/22
Karachun Rita A Sr. VP Fince-Global.. Sr. VP Fince-Global Controller May 03 Option 87.1 949 82,658 41,429 05/05/22
Klobuchar Michael A EVP - Chief Strategy.. EVP - Chief Strategy Officer May 03 Option 87.1 885 77,084 15,775 05/05/22
LeCointe-Cephas Lisa SVP Chief Ethics & C.. SVP Chief Ethics & Com Officer May 03 Option 87.1 813 70,812 3,943 05/05/22
Litchfield Caroline EVP & CFO EVP & CFO May 03 Option 87.65 773 67,753 27,799 05/04/22
Li Dean Y Executive VP & Presi.. Executive VP & President, MRL May 03 Option 87.65 773 67,753 16,839 05/04/22
Williams David Michael EVP,Chief Info&Digit.. EVP,Chief Info&Digital Officer May 03 Option 87.65 427 37,427 9,410 05/04/22
Williams David Michael EVP,Chief Info&Digit.. EVP,Chief Info&Digital Officer Feb 10 Option 76.53 1,202 91,989 7,421 02/14/22
Clyburn Frank EVP & Pres ? Human H.. EVP & Pres ? Human Health Oct 30 Option 29.35 42,120 1,236,222 136,857 11/02/21
Clyburn Frank EVP & Pres ? Human H.. EVP & Pres ? Human Health Oct 30 Sell 87.87 39,762 3,493,887 97,095 11/02/21
DeLuca Richard R. EVP&Pres, Merck Anim.. EVP&Pres, Merck Animal Heallth Oct 29 Option 0 135,405 252,335 11/02/21
DeLuca Richard R. EVP&Pres, Merck Anim.. EVP&Pres, Merck Animal Heallth Oct 29 Sell 87.56 135,405 11,856,062 116,930 11/02/21
Karachun Rita A Sr. VP Fince-Global.. Sr. VP Fince-Global Controller May 06 Option 75.98 1,212 92,088 36,215 05/06/21
LeCointe-Cephas Lisa SVP Chief Ethics & C.. SVP Chief Ethics & Com Officer May 06 Option 75.98 694 52,730 2,612 05/06/21
MIZELL STEVEN EVP, Chief HR Office.. EVP, Chief HR Officer Nov 03 Option 75.89 4,574 347,121 7,624 11/03/20
Davis Robert M EVP, Global Svcs & C.. EVP, Global Svcs & CFO Oct 06 Option 0 251,273 422,329 10/06/20
Davis Robert M EVP, Global Svcs & C.. EVP, Global Svcs & CFO Oct 06 Sell 81.03 251,273 20,360,651 171,056 10/06/20